Literature DB >> 16445367

Integrating novel agents into the curative treatment of head and neck cancer.

Robert Haddad, Aaron Allen, Lori Wirth, Roy Tishler, Marshall Posner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16445367     DOI： 10.1586/14737140.6.2.157

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN： 1473-7140            Impact factor:   4.512


× No keyword cloud information.
  2 in total

1.  A phase I clinical study of intratumorally administered VB4-845, an anti-epithelial cell adhesion molecule recombinant fusion protein, in patients with squamous cell carcinoma of the head and neck.

Authors:  G C MacDonald; M Rasamoelisolo; J Entwistle; W Cuthbert; M Kowalski; Maureen A Spearman; N Glover
Journal:  Med Oncol       Date:  2008-10-28       Impact factor: 3.064

2.  A phase I clinical study of VB4-845: weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck.

Authors:  Glen C MacDonald; Michèle Rasamoelisolo; Joycelyn Entwistle; Jeannick Cizeau; Denis Bosc; Wendy Cuthbert; Mark Kowalski; Maureen Spearman; Nick Glover
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.